Analyzing...
Loading company...
Indegene Ltd provides healthcare solutions through technology-enabled services. The company offers medical communications, commercial analytics, and digital marketing support to global pharmaceutical and biotech clients, helping them optimize patient engagement and market performance.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹3,510 Cr revenue.
COGS 0.0%, employees 62.6%.
“grew revenue by 30.”
“we have very clearly laid down that in the next six to eight quarters, we will get our margins back to, the levels you were at.”
“EBITDA is expected to begin sequential improvement from quarter one of FY twenty seven.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 12.8%▲ | 10.3% |
| ROCE | 15.4%▲ | 13.7% |
| Net Margin | 11.2%▲ | 7.6% |
| EBITDA Margin | 18.7%▲ | 15.4% |
| Debt To Equity | 0.00x▼ | 0.15x |
| (₹ Cr) | TTM | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | ₹3,813 Cr +34.3% | ₹2,839 Cr +9.6% | ₹2,590 Cr |
| Other Income | ₹79 Cr -26.4% | ₹107 Cr +40.5% | ₹76 Cr |
| Total Income | ₹3,892 Cr +32.1% | ₹2,947 Cr +10.5% | ₹2,666 Cr |
| ₹3,346 Cr +39.0% | ₹2,407 Cr +8.9% | ₹2,210 Cr | |
| Profit Before Tax | ₹526 Cr -2.5% | ₹539 Cr +17.6% | ₹459 Cr |
| Exceptional Items | (₹20 Cr) | ₹0.00 Cr -100.0% | ₹2 Cr |
| ₹125 Cr -6.0% | ₹133 Cr +8.8% | ₹122 Cr | |
| Net Profit | ₹401 Cr -1.4% | ₹407 Cr +20.8% | ₹337 Cr |
| Profit (Owners) | ₹401 Cr -1.4% | ₹407 Cr +20.8% | ₹337 Cr |
| Other Comprehensive Income | ₹135 Cr +425.4% | ₹26 Cr +224.1% | ₹8 Cr |
| EPS | ₹16.66 | ₹16.95 | ₹14.07 |
| Diluted Shares | ₹24 Cr | ₹24 Cr | ₹24 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Indegene Limited has informed the Exchange about Copy of Newspaper Publication
Indegene Limited has informed the Exchange about Link of recordings
Indegene Limited has informed the Exchange about Investor Presentation
Indegene Limited has informed the Exchange regarding a press release dated July 30, 2026, titled "Indegene Delivers Strong Q1 FY27 Performance, Revenue Up 39.7% YoY".
Monitoring Agency Report
Indegene Limited has informed the Exchange regarding allotment of 12451 securities pursuant to ESOP/ESPS at its meeting held on July 30, 2026
Indegene Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Indegene Limited has informed the Exchange about Copy of Newspaper Publication
Indegene Limited has informed the Exchange about Letter to Shareholders in relation to Annual Report of the Company for the financial year 2025-26
Indegene Limited has informed the Exchange about Business Responsibility and Sustainability Report for the financial year 2025-26
Indegene Limited has informed the Exchange about Shareholders meeting
Indegene Limited has informed the Exchange about Copy of Newspaper Publication
Indegene Limited has informed the Exchange that Record date for the purpose of Dividend is 31-Jul-2026.
Indegene Limited has informed the Exchange regarding Outcome of Board Meeting held on July 15, 2026.
Indegene Limited has informed the Exchange about Schedule of meet